Under AAAResearchReports.com Microscope: Repros Therapeutics Inc., Dendreon Corp., Novartis AG, and Stryker Corp.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, November 13, 2013 /PRNewswire/ --
On Tuesday, November 12, 2013, the S&P 500 ended the day at 1,767.69, down 0.24%; the Dow Jones Industrial Average closed at 15,750.67, down 0.21%; and the NASDAQ Composite finished flat at 3,919.92. Shares in the healthcare sector ended on a mixed note, even as the broader market closed lower. The major movers in the sector included Repros Therapeutics Inc. (NASDAQ: RPRX), Dendreon Corporation (NASDAQ: DNDN), Novartis AG (NYSE: NVS), and Stryker Corporation (NYSE: SYK). AAAResearchReports.com has released full comprehensive research on RPRX, DNDN, NVS, and SYK. These free technical analyses can be downloaded by signing up at:
http://www.aaaresearchreports.com/register/
On Tuesday, Repros Therapeutics Inc.'s stock ended the day at $14.99, which is 1.25% lower than the previous day's closing price of $15.18. The company's shares fluctuated between $14.55 and $15.40 during the trading session. A total of 0.42 million shares were traded, which is below the daily average volume of 0.77 million. Despite Tuesday's pullback, the company's shares have gained 0.62% in the previous three trading sessions, compared to a gain of 1.18% in the S&P 500 during the same period. Additionally, Repros Therapeutics Inc.'s stock is trading below its 50-day and 200-day moving averages of $22.78 and $17.97, respectively. A free technical analysis on RPRX available by signing up at:
http://www.AAAResearchReports.com/RPRX111313.pdf
Dendreon Corp.'s shares traded between $2.42 and $2.73 before finishing the day 3.20% higher at $2.58. A total of 9.25 million shares were traded, which is above the daily average volume of 4.45 million. The company's shares have gained 8.40% in the previous three trading sessions, outperforming the S&P 500, which has advanced 1.18% during the same period. However, Dendreon Corp.'s stock is trading below its 50-day and 200-day moving averages of $2.76 and $4.15, respectively. Register today and access free research on DNDN at:
http://www.AAAResearchReports.com/DNDN111313.pdf
Novartis AG.'s stock fluctuated between $77.92 and $78.41 before ending Tuesday's session 0.32% higher at $78.04. A total of 0.89 million shares were traded, which is below the daily average volume of 1.40 million. The company's shares have gained 4.12% in the last one month and 6.60% in the previous three months, outperforming the S&P 500, which has gained 3.79% and 4.63% during the respective periods. Moreover, Novartis AG.'s stock is trading near 52-week high of $79.64 and above its 50-day and 200-day moving averages of $76.29 and $72.82, respectively. The free report on NVS can be downloaded by signing up now at:
http://www.AAAResearchReports.com/NVS111313.pdf
On Tuesday, Stryker Corp.'s stock fell by 0.10% tracking losses in the broader market. The company's shares traded between $72.81 and $73.45 before finishing the day at $73.23. A total of 1.23 million shares were traded, which is less than the daily average volume of 1.33 million. Despite Tuesday's losses, the company's shares have gained 4.29% in the last one month and 3.49% in the previous three months, compared to a gain of 3.79% and 4.63% in the S&P 500 during the respective periods. Further, Stryker Corp.'s stock is trading near 52-week high of $74.86 and above its 50-day and 200-day moving averages of $70.90 and $67.61, respectively. A free report on SYK can be accessed by registering at:
http://www.AAAResearchReports.com/SYK111313.pdf
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AAAresearchreports.com
SOURCE AAA Research Reports
Share this article